Home - Products - Angiogenesis - c-Met/HGFR - Hepln-13

Hepln-13

CAS No. 64369-13-7

Hepln-13( Hepln 13 | Hepln13 )

Catalog No. M24659 CAS No. 64369-13-7

Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	115	In Stock
10MG	192	In Stock
25MG	385	In Stock
50MG	575	In Stock
100MG	801	In Stock
500MG	1647	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Hepln-13
Note

Research use only, not for human use.
Brief Description

Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
Description

Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
In Vitro

Hepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage.Western Blot Analysis Cell Line:293 cells Concentration:10 μM Incubation Time:2 hours Result:Inhibited cleavage.
In Vivo

HepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis.
Synonyms

Hepln 13 | Hepln13
Pathway

Angiogenesis
Target

c-Met/HGFR
Recptor

hepsin
Research Area

——
Indication

——

Chemical Information

CAS Number

64369-13-7
Formula Weight

325.2
Molecular Formula

C17H13BrN2
Purity

>98% (HPLC)
Solubility

DMSO:60 mg/mL?(184.50 mM;?Need ultrasonic)
SMILES

Brc1ccc(C(N2)Nc3cccc4cccc2c34)cc1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5(5):1352-1362.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Amivantamab

Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET).
Capmatinib hydrochlo...

Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).
palovarotene

Palovarotene is an agonist of nuclear retinoic acid receptor γ (RAR-γ).

Sign In Join Free